Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to $17.5 million.

  • Zevra Therapeutics' Other Non-Current Liabilities rose 21631.95% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 21631.95%. This contributed to the annual value of $14.4 million for FY2024, which is 9349.69% up from last year.
  • Per Zevra Therapeutics' latest filing, its Other Non-Current Liabilities stood at $17.5 million for Q3 2025, which was up 21631.95% from $17.5 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Other Non-Current Liabilities peaked at $17.5 million during Q2 2025, and registered a low of $14000.0 during Q1 2021.
  • Over the past 5 years, Zevra Therapeutics' median Other Non-Current Liabilities value was $319000.0 (recorded in 2023), while the average stood at $5.0 million.
  • Per our database at Business Quant, Zevra Therapeutics' Other Non-Current Liabilities crashed by 8842.98% in 2021 and then skyrocketed by 2973200.0% in 2023.
  • Zevra Therapeutics' Other Non-Current Liabilities (Quarter) stood at $31000.0 in 2021, then decreased by 19.35% to $25000.0 in 2022, then skyrocketed by 29732.0% to $7.5 million in 2023, then surged by 93.5% to $14.4 million in 2024, then rose by 21.02% to $17.5 million in 2025.
  • Its Other Non-Current Liabilities was $17.5 million in Q3 2025, compared to $17.5 million in Q2 2025 and $16.2 million in Q1 2025.